Geoffrey J Yuen

Summary

Affiliation: Glaxo Wellcome
Country: USA

Publications

  1. ncbi Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily
    Geoffrey J Yuen
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 48:176-82. 2004
  2. ncbi Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects
    Susan L Ford
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Antimicrob Agents Chemother 52:534-8. 2008
  3. ncbi A review of the pharmacokinetics of abacavir
    Geoffrey J Yuen
    Clinical Pharmacology, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, Durham, NC 27709, USA
    Clin Pharmacokinet 47:351-71. 2008
  4. ncbi Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men
    Julie B Dumond
    University of North Carolina at Chapel Hill, 3318 Kerr Hall, CB 7360, Chapel Hill, NC 27599 7360, USA
    J Acquir Immune Defic Syndr 48:156-62. 2008
  5. ncbi Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients
    Gail Skowron
    Roger Williams Medical Center, Providence, Rhode Island 02908, USA
    J Infect Dis 186:1028-33. 2002
  6. ncbi Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure
    Ashwin Asari
    Department of Renal Medicine, Manchester Royal Infirmary, Manchester, UK
    Br J Clin Pharmacol 64:738-44. 2007

Collaborators

Detail Information

Publications6

  1. ncbi Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily
    Geoffrey J Yuen
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 48:176-82. 2004
    ..Overall, the results of this study suggest that for key AUC-related parameters, lamivudine at 300 mg once daily is pharmacokinetically equivalent to lamivudine at 150 mg twice daily...
  2. ncbi Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects
    Susan L Ford
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Antimicrob Agents Chemother 52:534-8. 2008
    ..Based on the results of this study, a reduction in the RFB dose by > or =75% (to 150 mg QOD or three times per week) is recommended when it is coadministered with FPV-RTV (700/100 mg BID)...
  3. ncbi A review of the pharmacokinetics of abacavir
    Geoffrey J Yuen
    Clinical Pharmacology, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, Durham, NC 27709, USA
    Clin Pharmacokinet 47:351-71. 2008
    ..No clinically significant drug interactions have been observed between recommended doses of abacavir and lamivudine, zidovudine, alcohol (ethanol) or methadone...
  4. ncbi Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men
    Julie B Dumond
    University of North Carolina at Chapel Hill, 3318 Kerr Hall, CB 7360, Chapel Hill, NC 27599 7360, USA
    J Acquir Immune Defic Syndr 48:156-62. 2008
    ..To quantitate extracellular and intracellular zidovudine (ZDV) and lamivudine (3TC) concentrations in blood and semen of HIV-1-infected men...
  5. ncbi Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients
    Gail Skowron
    Roger Williams Medical Center, Providence, Rhode Island 02908, USA
    J Infect Dis 186:1028-33. 2002
    ....
  6. ncbi Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure
    Ashwin Asari
    Department of Renal Medicine, Manchester Royal Infirmary, Manchester, UK
    Br J Clin Pharmacol 64:738-44. 2007
    ..To establish whether peritoneal dialysis (PD) requires dosing modification from the CL(CR)-corrected lamivudine dose in end-stage renal failure subjects...